Compare Freeport-McMoRan Inc (FCX) vs Natera Inc. Common Stock (NTRA) Price & Performance

FCX trades at $72.42, down 1.19% today, with a bullish technical signal from moving averages and a consensus analyst price target of $73.50. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue reached $25.92B in 2025, and net income margin improved to 11.38%. Strong cash flow from operations of $5.61B supports dividend payments and growth projects amid rising copper demand driven by AI and data centers.

FCX presents a positive outlook with robust fundamentals and favorable copper market dynamics, but faces risks from cost pressures and regulatory scrutiny. Earnings growth and expansion initiatives are key catalysts, while investor sentiment remains bullish based on analyst ratings.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.